Shanghai Fosun Pharmaceutical Stock Net Income
| SFOSFDelisted Stock | USD 2.67 0.00 0.00% |
As of the 26th of January, Shanghai Fosun has the Risk Adjusted Performance of 0.0995, variance of 20.08, and Coefficient Of Variation of 803.58. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Shanghai Fosun Pharm, as well as the relationship between them. Please validate Shanghai Fosun Pharm mean deviation and treynor ratio to decide if Shanghai Fosun is priced more or less accurately, providing market reflects its prevalent price of 2.67 per share. Please also confirm Shanghai Fosun Pharmaceutical information ratio, which is currently at 0.107 to double-check the company can sustain itself at a future point.
Shanghai Fosun's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Shanghai Fosun's valuation are provided below:Shanghai Fosun Pharmaceutical does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Shanghai |
Search Suggestions
| S | SentinelOne | Company |
| S | Sonic Labs | Cryptocurrency |
| SOJC | Southern Co | Company |
| SBI | Western Asset Intermediate | Fund |
| SH | ProShares Short SP500 | ETF |
| SML | SP Small-Cap 600 | Index |
| SIUSD | Silver Futures | Commodity |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Shanghai Fosun Pharmaceutical reported net income of 4.74 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is significantly lower than that of the firm.
Shanghai Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Fosun's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Shanghai Fosun could also be used in its relative valuation, which is a method of valuing Shanghai Fosun by comparing valuation metrics of similar companies.Shanghai Fosun is currently under evaluation in net income category among its peers.
Shanghai Fundamentals
| Return On Equity | 0.0756 | |||
| Return On Asset | 0.0204 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 15.52 B | |||
| Shares Outstanding | 551.94 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 35.60 % | |||
| Price To Earning | 13.80 X | |||
| Price To Book | 1.45 X | |||
| Price To Sales | 0.31 X | |||
| Revenue | 39.01 B | |||
| Gross Profit | 18.71 B | |||
| EBITDA | 8.71 B | |||
| Net Income | 4.74 B | |||
| Cash And Equivalents | 14.64 B | |||
| Cash Per Share | 5.49 X | |||
| Total Debt | 9.05 B | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 1.00 X | |||
| Book Value Per Share | 16.30 X | |||
| Cash Flow From Operations | 3.95 B | |||
| Earnings Per Share | 0.21 X | |||
| Number Of Employees | 36.28 K | |||
| Beta | 0.76 | |||
| Market Capitalization | 12.25 B | |||
| Total Asset | 93.29 B | |||
| Retained Earnings | 10.37 B | |||
| Working Capital | (817 M) | |||
| Current Asset | 10.27 B | |||
| Current Liabilities | 11.09 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 93.29 B | |||
| Last Dividend Paid | 0.56 |
About Shanghai Fosun Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Fosun Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Fosun using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Fosun Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Shanghai Pink Sheet
If you are still planning to invest in Shanghai Fosun Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Shanghai Fosun's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |